米氮平治疗男男性行为者甲基苯丙胺使用障碍的随机对照试验
这项双盲随机对照试验在旧金山门诊研究诊所进行,纳入120名与男性发生性行为的顺性别男性和跨性别女性甲基苯丙胺使用障碍者,随机接受米氮平30mg每日一次或安慰剂24周并随访12周。结果显示米氮平组在第12、24、36周尿检甲基苯丙胺阳性率显著低于安慰剂组,且第24周部分HIV风险行为和抑郁、失眠症状改善,无药物相关严重不良事件。
要点
- 米氮平30mg每日一次联合咨询可降低甲基苯丙胺使用障碍者的尿检阳性率。
- 第24周米氮平组性伴侣数及血清不一致无套肛交次数减少。
- 米氮平组抑郁和失眠症状评分改善,无药物相关严重不良事件。
核心结论
- 在扩展重复试验中,米氮平联合物质使用咨询减少了顺性别男性和跨性别女性的甲基苯丙胺使用及部分HIV风险行为,且疗效在治疗结束后仍持续。
研究设计与样本
- 双盲随机安慰剂对照临床试验,2013年8月至2017年9月在旧金山门诊研究诊所进行,纳入120名社区招募的与男性发生性行为的顺性别男性和跨性别女性。
- 参与者随机接受米氮平30mg或匹配安慰剂口服每日一次共24周,并辅以背景咨询,随后随访12周。
主要发现
- 第12周米氮平组尿检甲基苯丙胺阳性率显著低于安慰剂组(RR 0.67,95%CI 0.51-0.87)。
- 第24周(RR 0.75,95%CI 0.56-1.00)和第36周(RR 0.73,95%CI 0.57-0.96)米氮平组尿检阳性率均低于安慰剂组。
关键数值与推荐
- 米氮平30mg口服每日一次,联合背景咨询,疗程24周。
- 主要结局为第12、24、36周尿检甲基苯丙胺阳性率。
临床怎么用
- 对于与男性发生性行为的顺性别男性和跨性别女性甲基苯丙胺使用障碍者,可考虑米氮平30mg每日一次联合咨询以减少甲基苯丙胺使用和部分HIV风险行为。
- 米氮平可能同时改善抑郁症状和失眠严重程度,且未观察到药物相关严重不良事件。
局限性
- 服药依从性欠佳,WisePill记录的依从率在米氮平组第2-12周为38.5%、第13-24周为28.1%。
- 研究样本以顺性别男性为主(115/120),跨性别女性仅5人,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Methamphetamine use is increasingly prevalent and associated with HIV transmission. A previous phase 2a study of mirtazapine demonstrated reductions in methamphetamine use and sexual risk behaviors among men who have sex with men. OBJECTIVE: To determine the efficacy of mirtazapine for treatment of methamphetamine use disorder and reduction in HIV risk behaviors. DESIGN, SETTING, AND PARTICIPANTS: This double-blind randomized clinical trial of mirtazapine vs placebo took place from August 2013 to September 2017 in an outpatient research clinic in San Francisco, California. Participants were community-recruited adults who were sexually active; cisgender men, transgender men, and transgender women who (1) had sex with men, (2) had methamphetamine use disorder, and (3) were actively using methamphetamine were eligible. Participants were randomized to receive the study drug or placebo for 24 weeks, with 12 more weeks of follow-up. Data analysis took place from February to June 2018. EXPOSURES: Mirtazapine, 30 mg, or matched placebo orally once daily for 24 weeks, with background counseling. MAIN OUTCOMES AND MEASURES: Positive urine test results for methamphetamine over 12, 24, and 36 weeks (primary outcomes) and sexual risk behaviors (secondary outcomes). Sleep, methamphetamine craving, dependence severity, and adverse events were assessed. RESULTS: Of 241 persons assessed, 120 were enrolled (5 transgender women and 115 cisgender men). The mean (SD) age was 43.3 (9.8) years; 61 (50.8%) were white, 31 (25.8%) were African American, and 15 (12.5%) were Latinx. A mean (SD) of 66% (47%) of visits were completed overall. By week 12, the rate of methamphetamine-positive urine test results significantly declined among participants randomized to mirtazapine vs placebo (risk ratio [RR], 0.67 [95% CI, 0.51-0.87]). Mirtazapine resulted in reductions in positive urine test results at 24 weeks (RR, 0.75 [95% CI, 0.56-1.00]) and 36 weeks (RR, 0.73 [95% CI, 0.57-0.96]) vs placebo. Mean (SD) medication adherence by WisePill dispenser was 38.5% (27.0%) in the mirtazapine group vs 39.5% (26.2%) in the placebo group (P = .77) over 2 to 12 weeks and 28.1% (23.4%) vs 38.5% (27.0%) (P = .59) over 13 to 24 weeks. Changes in sexual risk behaviors were not significantly different by study arm at 12 weeks, but those assigned to receive mirtazapine had fewer sexual partners (RR, 0.52 [95% CI, 0.27-0.97]; P = .04), fewer episodes of condomless anal sex with partners who were serodiscordant (RR, 0.47 [95% CI, 0.23-0.97]; P = .04), and fewer episodes of condomless receptive anal sex with partners who were serodiscordant (RR, 0.37 [95% CI, 0.14-0.93]; P = .04) at week 24. Participants assigned to mirtazapine had net reductions in depressive symptoms (Center for Epidemiologic Studies Depression Scale score, 6.2 [95% CI, 1.3-11.1] points lower; P = .01) and insomnia severity (Athens score, 1.4 [95% CI, 0.1-2.7] points lower; P = .04) at week 24. There were no serious adverse events associated with the study drug. CONCLUSIONS AND RELEVANCE: In this expanded replication trial, adding mirtazapine to substance use counseling reduced methamphetamine use and some HIV risk behaviors among cisgender men and transgender women who have sex with men, with benefits extending after treatment despite suboptimal medication adherence. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01888835.
引用
- Coffin PO, Santos GM, Hern J, et al. Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial. JAMA Psychiatry. 2020. PMID: 31825466. doi:10.1001/jamapsychiatry.2019.3655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。